Paolo Codega

Paolo Codega

Auto-generated profile, based on publicly available information

Paolo Codega

Medical Affairs Department, Italfarmaco SpA, Cinisello Balsamo, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Neuron
Verified
Journal Article
Closed access
PCPaolo Codega
Paolo Codega
VSVioleta Silva-Vargas
Violeta Silva-Vargas
APAlex Paul
Alex Paul
AMAngel R. Maldonado-Soto
Angel R. Maldonado-Soto
ADAnnina M. DeLeo
Annina M. DeLeo
FDFiona Doetsch
Fiona Doetsch

1 November 2016 in Cell Stem Cell
Verified
Journal Article
Closed access
VSVioleta Silva-Vargas
Violeta Silva-Vargas
AMAngel R. Maldonado-Soto
Angel R. Maldonado-Soto
DMDogukan Mizrak
Dogukan Mizrak
PCPaolo Codega
Paolo Codega
FDFiona Doetsch
Fiona Doetsch

31 January 2019 in Blood
Verified
Journal Article
Closed access
PDF file
CGChristian Grommes
Christian Grommes
STSarah S. Tang
Sarah S. Tang
JWJulia Wolfe
Julia Wolfe
TKThomas J. Kaley
Thomas J. Kaley
MDMariza Daras
Mariza Daras
IMIngo K. Mellinghoff
Ingo K. Mellinghoff
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-agent activity in recurrent/refractory (r/r) central nervous system lymphoma (CNSL). Clinical responses are often transient or incomplete, suggesting a need for a combination therapy approach. We conducted a Phase Ib clinical trial to explore the sequential combination of ibrutinib at 560 or 840 mg daily dosing with methotrexate (HD-MTX) and rituximab in patients with CNSL. HD-MTX was given at 3.5g/m2 every 2 weeks for a total of 8 doses (4 cycles; cycle = 28 days). Ibrutinib was held on days of HD-MTX infusion and resumed 5 days after HD-MTX infusion or after HD-MTX-clearance. Single-agent daily ibrutinib was administered continuously after completion of induction therapy until disease progression, intolerable toxicity, or death. We also explored next-generation sequencing of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) before and during treatment. The combination of ibrutinib, HD-MTX and rituximab was tolerated with acceptable safety profile (no grade 5 events, 3 grade 4 events). No dose-limiting toxicity was observed. 11/15 patients proceeded to maintenance ibrutinib after completing four cycles of the ibrutinib/HD-MTX/rituximab combination. Clinical responses occurred in 12/15 patients (80%). Sustained tumor responses were associated with clearance of ctDNA from the CSF. The study is registered to https://clinicaltrials.gov as NCT02315326. Key points Ibrutinib/methotrexate/rituximab combination treatment is safe and shows promising clinical activity in CNS lymphoma. Circulating tumor DNA analysis of cerebrospinal fluid may be useful to monitor disease burden in patients with CNS lymphoma.

20 September 2016 in WIREs Developmental Biology
Verified
Journal Article
Open access
PDF file
ZCZayna Chaker
Zayna Chaker
PCPaolo Codega
Paolo Codega
FDFiona Doetsch
Fiona Doetsch
Neural stem cells (NSCs) reside in specialized niches in the adult mammalian brain. The ventricular–subventricular zone (V‐SVZ), adjacent to the lateral ventricles, gives rise to olfactory bulb (OB) neurons, and some astrocytes and oligodendrocytes throughout life. In vitro assays have been widely used to retrospectively identify NSCs. However, cells that behave as stem cells in vitro do not reflect the identity, diversity, and behavior of NSCs in vivo. Novel tools including fluorescence activated cell sorting, lineage‐tracing, and clonal analysis have uncovered multiple layers of adult V‐SVZ NSC heterogeneity, including proliferation state and regional identity. In light of these findings, we reexamine the concept of adult NSCs, considering heterogeneity as a key parameter for analyzing their dynamics in vivo. V‐SVZ NSCs form a mosaic of quiescent (qNSCs) and activated cells (aNSCs) that reside in regionally distinct microdomains, reflecting their regional embryonic origins, and give rise to specific subtypes of OB interneurons. Prospective purification and transcriptome analysis of qNSCs and aNSCs has illuminated their molecular and functional properties. qNSCs are slowly dividing, have slow kinetics of neurogenesis in vivo, can be recruited to regenerate the V‐SVZ, and only rarely give rise to in vitro colonies. aNSCs are highly proliferative, undergo rapid clonal expansion of the neurogenic lineage in vivo, and readily form in vitro colonies. Key open questions remain about stem cell dynamics in vivo and the lineage relationship between qNSCs and aNSCs under homeostasis and regeneration, as well as context‐dependent plasticity of regionally distinct adult NSCs under different external stimuli. WIREs Dev Biol 2016, 5:640–658. doi: 10.1002/wdev.248This article is categorized under: Adult Stem Cells, Tissue Renewal, and Regeneration > Methods and Principles Adult Stem Cells, Tissue Renewal, and Regeneration > Tissue Stem Cells and Niches Adult Stem Cells, Tissue Renewal, and Regeneration > Stem Cells and Aging

2 March 2005 in FEBS Letters
Verified
Journal Article
Closed access
AGAlejandro Giorgetti
Alejandro Giorgetti
ANAnil V. Nair
Anil V. Nair
PCPaolo Codega
Paolo Codega
VTVincent Torre
Vincent Torre
PCPaolo Carloni
Paolo Carloni

11 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
BOBarbara Oldrini
Barbara Oldrini
WHWan-Ying Hsieh
Wan-Ying Hsieh
HEHediye Erdjument-Bromage
Hediye Erdjument-Bromage
PCPaolo Codega
Paolo Codega
MCMaria Stella Carro
Maria Stella Carro
IMIngo K. Mellinghoff
Ingo K. Mellinghoff
Transport of macromolecules through the nuclear pore by importins and exportins plays a critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote tumorigenesis remains unclear. The epidermal growth factor receptor (EGFR) plays a critical role in normal development and in human cancer. Here we describe a mechanism of EGFR regulation through the importin β family member RAN-binding protein 6 (RanBP6), a protein of hitherto unknown functions. We show that RanBP6 silencing impairs nuclear translocation of signal transducer and activator of transcription 3 (STAT3), reduces STAT3 binding to the EGFR promoter, results in transcriptional derepression of EGFR, and increased EGFR pathway output. Focal deletions of the RanBP6 locus on chromosome 9p were found in a subset of glioblastoma (GBM) and silencing of RanBP6 promoted glioma growth in vivo. Our results provide an example of EGFR deregulation in cancer through silencing of components of the nuclear import pathway.